Quoin Q2 net loss $5.4M; FDA clears first-ever IND for Peeling Skin Syndrome

Quoin Pharmaceuticals, Ltd.

Q2 2026 net loss $5.4M vs $3.7M in Q2 2025; six-month loss $10.4M vs $7.5M.
Cash, equivalents, and marketable securities $10.8M as of June 30, 2026; funds operations into 2027.
FDA conditionally approved QYLEKI as brand name for QRX003 (Netherton Syndrome) on June 23, 2026.
FDA cleared IND for QRX003 in Peeling Skin Syndrome on July 9, 2026; Phase 2/3 study to start 2H 2026.
USPTO issued Notice of Allowance for patent covering combination treatment for Netherton Syndrome on June 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.